4//SEC Filing
Ostertag Eric 4
Accession 0001209191-22-006170
CIK 0001661460other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 9:48 PM ET
Size
17.1 KB
Accession
0001209191-22-006170
Insider Transaction Report
Form 4
Ostertag Eric
DirectorChief Executive Officer10% Owner
Transactions
- Gift
Common Stock
2021-12-30−93,955→ 603,467 total - Award
Employee Stock Option (Right to Buy)
2022-02-01+118,708→ 118,708 totalExercise: $4.75Exp: 2032-01-31→ Common Stock (118,708 underlying) - Award
Employee Stock Option (Right to Buy)
2022-02-01+10,792→ 10,792 totalExercise: $5.23Exp: 2027-01-31→ Common Stock (10,792 underlying) - Gift
Common Stock
2021-12-30−48,902→ 580,292 total(indirect: See footnote) - Award
Common Stock
2022-02-01+89,500→ 692,967 total
Holdings
- 160,696(indirect: See footnote)
Common Stock
- 3,659,503(indirect: See footnote)
Common Stock
- 3,358,455(indirect: See footnote)
Common Stock
- 961,445(indirect: See footnote)
Common Stock
Footnotes (8)
- [F1]The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
- [F2]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in two equal annual installments.
- [F3]The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
- [F4]The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F5]The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
- [F6]The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
- [F7]25% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 18 equal monthly installments thereafter.
- [F8]The exercise price of the incentive stock option is equal to 110% of the fair market value of the Issuer's common stock on the date of grant, due to the reporting person's status as the beneficial owner of 10% or more of the Issuer's common stock on the grant date.
Documents
Issuer
Poseida Therapeutics, Inc.
CIK 0001661460
Entity typeother
Related Parties
1- filerCIK 0001765987
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 9:48 PM ET
- Size
- 17.1 KB